A prostate cancer drug for terminal patients, which can put the disease on hold for a year, has been approved by UK regulators.
The Medicines and Healthcare Regulatory Agency (MHRA) has ruled in favour of Pluvicto, which could delay the progression of disease by more than a year.
Cancer experts said it was a “major clinical advance”, giving fresh hope to men with metastatic disease.
